Twist Bioscience (TWST) 10-Q 11 Feb 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2018	Feb. 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Trading Symbol	TWST
Entity Registrant Name	Twist Bioscience Corp
Entity Central Index Key	1,581,280
Current Fiscal Year End Date	--09-30
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		28,017,924

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Current assets
Cash and cash equivalents	$ 66,459	$ 80,757
Short-term investments	63,707
Accounts receivable, net	6,978	5,419
Inventory	5,561	6,028
Prepaid expenses and other current assets	3,958	3,467
Total current assets	146,663	95,671
Property and equipment, net	13,596	12,331
Goodwill	1,138	1,138
Intangible assets, net	661	712
Restricted cash, non-current	579	579
Other non-current assets	1,816	5,360
Total assets	164,453	115,791
Current liabilities
Accounts payable	6,725	7,531
Accrued expenses	2,606	2,166
Accrued payroll	5,261	5,401
Current portion of long-term debt	3,333	2,500
Other current liabilities	1,073	939
Total current liabilities	18,998	18,537
Redeemable convertible preferred stock warrant liability		631
Long-term debt, net of current portion	6,526	7,218
Other non-current liabilities	333	344
Total liabilities	25,857	26,730
Commitments and contingencies
Redeemable convertible preferred stock		290,483
Stockholders' equity (deficit)
Preferred stock
Common stock	0	0
Additional paid-in capital	372,066	9,346
Accumulated other comprehensive income	24	87
Accumulated deficit	(233,494)	(210,855)
Total stockholders' equity (deficit)	138,596	(201,422)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$ 164,453	115,791
Series A Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		9,141
Series B Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		25,900
Series C Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		36,726
Series D Redeemable Convertible Preferred Stock [Member]
Current liabilities
Redeemable convertible preferred stock		$ 218,716

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Sep. 30, 2018
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, share authorized	10,000,000	0
Preferred stock, share issued	0	0
Preferred stock, share outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, share authorized	100,000,000	27,775,000
Common stock, share issued	28,012,874	3,206,048
Common stock, share outstanding	28,012,874	3,206,048
Series A Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable convertible preferred stock, share authorized	0	2,854,576
Redeemable convertible preferred stock, share issued	0	2,817,723
Redeemable convertible preferred stock, share outstanding	0	2,817,723
Series B Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable convertible preferred stock, share authorized	0	3,331,878
Redeemable convertible preferred stock, share issued	0	3,315,645
Redeemable convertible preferred stock, share outstanding	0	3,315,645
Series C Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable convertible preferred stock, share authorized	0	2,510,354
Redeemable convertible preferred stock, share issued	0	2,491,483
Redeemable convertible preferred stock, share outstanding	0	2,491,483
Series D Redeemable Convertible Preferred Stock [Member]
Redeemable convertible preferred stock, par value	$ 0.00001	$ 0.00001
Redeemable convertible preferred stock, share authorized	0	10,475,252
Redeemable convertible preferred stock, share issued	0	10,326,454
Redeemable convertible preferred stock, share outstanding	0	10,326,454

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Comprehensive Income [Abstract]
Revenues	$ 11,492	$ 4,313
Operating expenses:
Cost of revenues	11,857	7,498
Research and development	7,273	4,303
Selling, general and administrative	15,259	9,263
Total operating expenses	34,389	21,064
Loss from operations	(22,897)	(16,751)
Interest income	664	158
Interest expense	(348)	(273)
Other income (expense), net	(15)	(19)
Loss before income taxes	(22,596)	(16,885)
Provision for income taxes	(43)	(52)
Net loss attributable to common stockholders	(22,639)	(16,937)
Other comprehensive loss:
Change in unrealized loss on investments	(7)	(1)
Foreign currency translation adjustment	(56)	10
Comprehensive loss	$ (22,702)	$ (16,928)
Net loss per share attributable to common stockholders-basic and diluted	$ (1.18)	$ (6.42)
Weighted average shares used in computing net loss per share attributable to common stockholders-basic and diluted	19,187,533	2,638,068

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total		Series A Redeemable Convertible Preferred Stock [Member]	Series B Redeemable Convertible Preferred Stock [Member]	Series C Redeemable Convertible Preferred Stock [Member]	Series D Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Other Comprehensive Income [Member]	Accumulated deficit [Member]
Beginning Balance at Sep. 30, 2017			$ 9,141	$ 25,900	$ 36,726	$ 127,866
Beginning Balance , shares at Sep. 30, 2017			2,817,723	3,315,645	2,491,483	6,034,089
Conversion of redeemable convertible preferred stock to common stock						$ 2,990
Conversion of redeemable convertible preferred stock to common stock , shares						141,212
Ending Balance at Dec. 31, 2017			$ 9,141	$ 25,900	$ 36,726	$ 130,856
Ending Balance , shares at Dec. 31, 2017			2,817,723	3,315,645	2,491,483	6,175,301
Beginning Balance at Sep. 30, 2017	$ (133,358)							$ 6,228	$ 33	$ (139,619)
Beginning Balance , shares at Sep. 30, 2017							3,178,819
Exercise of stock options	47							47
Exercise of stock options , shares							33,906
Repurchases of early exercised common stock options	0						$ 0	0	0	0
Repurchases of early exercised common stock options , shares							(757)
Stock based compensation	536							536
Other comprehensive income	9								9
Net loss	(16,937)	[1]								(16,937)
Ending Balance at Dec. 31, 2017	(149,703)							6,811	42	(156,556)
Ending Balance , shares at Dec. 31, 2017							3,211,968
Beginning Balance at Sep. 30, 2018	290,483		$ 9,141	$ 25,900	$ 36,726	$ 218,716
Beginning Balance , shares at Sep. 30, 2018			2,817,723	3,315,645	2,491,483	10,326,454
Conversion of redeemable convertible preferred stock to common stock			$ 9,141	$ 25,900	$ 36,726	$ 218,716
Conversion of redeemable convertible preferred stock to common stock , shares			2,817,723	3,315,645	2,491,483	10,326,454
Ending Balance , shares at Dec. 31, 2018			0	0	0	0
Beginning Balance at Sep. 30, 2018	(201,422)							9,346	$ 87	$ (210,855)
Beginning Balance , shares at Sep. 30, 2018							3,206,048
Issuance of common stock in public offering	69,597							69,597
Issuance of common stock in public offering, shares							5,750,000
Exercise of stock options	$ 166							166
Exercise of stock options , shares	48,841						48,841
Conversion of redeemable convertible preferred stock warrant liability to equity	$ 631							$ 631
Conversion of redeemable convertible preferred stock warrant liability to equity , shares	0						0	0	0	0
Conversion of redeemable convertible preferred stock to common stock	$ 290,462							$ 290,462
Conversion of redeemable convertible preferred stock to common stock , shares							18,951,305
Repurchases of early exercised common stock options	0						$ 0	0	$ 0	$ 0
Repurchases of early exercised common stock options , shares							(442)
Net exercise of stock warrants							57,122
Stock based compensation	1,864							1,864
Other comprehensive income	(63)								(63)
Net loss	(22,639)									(22,639)
Ending Balance at Dec. 31, 2018	$ 138,596							$ 372,066	$ 24	$ (233,494)
Ending Balance , shares at Dec. 31, 2018							28,012,874
[1]	Adjusted to reflect the retrospective adoption of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net of underwriting discounts, commissions and offering expenses	$ 10,903
Series D Redeemable Convertible Preferred Stock [Member]
Issuance of redeemable convertible preferred stock, net of financing cost		$ 10

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss		$ (22,639)	$ (16,937)	[1]
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		1,472	1,286	[1]
Loss on disposal of property and equipment		8
Stock-based compensation		1,864	536	[1]
Non-cash interest expense		64	17	[1]
Change in fair value of redeemable convertible preferred stock warrant liability	[1]		(2)
Amortization of debt discount		78	93	[1]
Changes in assets and liabilities, net of impact of business combination:
Accounts receivable, net		(1,559)	(677)	[1]
Inventory		467	(446)	[1]
Prepaid expenses and other current assets		(366)	90	[1]
Other non-current assets		(392)	(111)	[1]
Accounts payable		(715)	954	[1]
Accrued expenses		39	(662)	[1]
Accrued payroll		(140)	(72)	[1]
Other liabilities		135	(85)	[1]
Net cash used in operating activities		(21,684)	(16,016)	[1]
Cash flows from investing activities
Purchases of property and equipment		(1,922)	(1,511)	[1]
Purchases of investments		(63,835)	(3,374)	[1]
Maturity of investments	[1]		13,100
Net cash provided by (used in) investing activities		(65,757)	8,215	[1]
Cash flows from financing activities
Proceeds from issuance of common stock and exercise of stock options		220	142	[1]
Proceeds from initial public offering, net of underwriting discounts, commissions and offering expenses		72,779
Proceeds from issuance of Series D redeemable convertible preferred stock, net of issuance costs	[1]		2,990
Payments of deferred offering costs	[1]		(470)
Net cash provided by financing activities		72,999	2,662	[1]
Net decrease in cash, cash equivalents, and restricted cash		(14,442)	(5,139)	[1]
Cash, cash equivalents, and restricted cash at beginning of period		81,537	31,429	[1]
Cash, cash equivalents, and restricted cash at end of period		67,095	26,290	[1]
Supplemental disclosure of cash flow information
Interest paid		207	203	[1]
Income taxes paid, net of refunds		53	5	[1]
Non-cash investing and financing activities
Property and equipment additions included in accounts payable and accrued expenses		1,117	226	[1]
Deferred offering costs included in accounts payable and accrued expenses		826	$ 87	[1]
Conversion of redeemable convertible preferred stock warrant liability to equity		631
Conversion of redeemable convertible preferred stock to common stock		$ 290,462
[1]	Adjusted to reflect the retrospective adoption of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

The Company

The Company	3 Months Ended
	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Twist Bioscience Corporation (the Company) was incorporated in the state of Delaware on February 4, 2013. The Company is a synthetic biology company that has developed a disruptive DNA synthesis platform. The Company’s fiscal year ends September 30. The Company has generated net losses in all periods since inception. As of December 31, 2018, the Company had an accumulated deficit of $233.5 million and has not generated positive cash flows from operations since inception. Losses are expected to continue as the Company continues to invest in product development, manufacturing, and sales and marketing. The Company has raised multiple rounds of debt and equity financing since its inception. In October 2018, the Company completed an initial public offering (IPO) of its common stock which raised proceeds of $69.6 million, after deducting underwriting discounts, commissions and offering expenses. Management believes that these proceeds combined with existing cash and short-term investment balances on hand will be sufficient to fund operations for at least one year from the issuance of these unaudited condensed consolidated financial statements. However, there can be no assurance that additional financing will not be required or that the Company will be successful in raising additional capital on terms which are acceptable to the Company. If the Company requires but is unable to obtain additional funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations.

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of significant accounting policies	2. Summary of significant accounting policies Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly-owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation. Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K. Reverse stock split In October 2018, the Company’s stockholders approved a one-for-0.101 Deferred offering costs Deferred offering costs, which consist of direct incremental legal, consulting, banking and accounting fees relating to the Company’s IPO, are capitalized and will be offset against proceeds from the IPO within stockholders’ equity. As of September 30, 2018, there was $3.7 million of deferred offering costs within other non-current Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued new lease accounting guidance in ASU 2016-02, Leases right-of-use In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments zero-coupon 2016-15 In November 2016, the FASB has issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash beginning-of-period end-of-period non-current (in thousands) September 30, December 31, Cash and cash equivalents $ 80,757 $ 66,459 Restricted cash, non-current 579 579 Restricted cash, current (within prepaid expenses and other current assets) 201 57 Total cash, cash equivalents and restricted cash $ 81,537 $ 67,095 Amounts included in restricted cash primarily relate to security deposits and a letter of credit with a financial institution, both in connection with office space lease agreements. In January 2017, the FASB has issued ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In May 2017, the FASB issued ASU 2017-09, Compensation Stock Compensation (Topic 718): Scope of Modification Accounting 2017-09, In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-14

Fair value measurement

Fair value measurement	3 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Fair value measurement	3. Fair value measurement The Company assesses the fair value of financial instruments based on the provisions of ASC 820, Fair Value Measurements. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company short-term investments primarily utilizes broker quotes in a non-active Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2018 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. September 30, 2018 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash and cash equivalents $ 46,823 $ — $ — $ 46,823 Money market funds 33,934 — — 33,934 Totals $ 80,757 $ — $ — $ 80,757 Liabilities Redeemable convertible preferred stock warrant liability $ — $ — $ 631 $ 631 December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash and cash equivalents $ 21,041 $ — $ — $ 21,041 Money market funds 39,321 — — 39,321 Corporate bonds — 2,993 — 2,993 Commercial paper — 28,707 — 28,707 U.S. government treasury bills 38,104 — — 38,104 Totals $ 98,466 $ 31,700 $ — $ 130,166 As of September 30, 2018 and December 31, 2018, gross unrealized gains and unrealized losses for cash equivalents and short-term investments were not material, and the contractual maturity of all marketable securities were less than one year. Redeemable convertible preferred stock warrants The following table provides a reconciliation of beginning and ending balances of the Level 3 instruments during the three months ended December 31, 2017 and 2018: December 31, 2017 (in thousands) Series A Series B Series C Series D Total Fair value as of September 30, 2017 $ 331 $ 110 $ 152 $ 51 $ 644 Change in fair value recorded in other income (expense), net 6 5 (12 ) (1 ) (2 ) Fair value as of December 31, 2017 $ 337 $ 115 $ 140 $ 50 $ 642 December 31, 2018 (in thousands) Series A Series B Series C Series D Total Fair value as of September 30, 2018 $ 365 $ 94 $ 130 $ 42 $ 631 Conversion of redeemable convertible preferred stock warrants to common stock warrants (365 ) (94 ) (130 ) (42 ) (631 ) Fair value as of December 31, 2018 $ — $ — $ — $ — $ —

Inventory

Inventory	3 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory	4. Inventory Inventory consists of the following: (in thousands) September 30, December 31, Raw Materials $ 2,988 $ 3,351 Work-in-process 2,273 1,599 Finished Goods 767 611 $ 6,028 $ 5,561

Goodwill and intangible assets

Goodwill and intangible assets	3 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and intangible assets	5. Goodwill and intangible assets There were no changes to the carrying value of goodwill during the three months ended December 31, 2017 and 2018. Total amortization expense related to intangible assets was less than $0.1 million for each of the three months ended December 31, 2017 and 2018. The intangible assets balances are presented below: September 30, 2018 (in thousands, except for years) Useful Gross Accumulated Net book Developed Technology 6 $ 1,220 $ (508 ) $ 712 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (528 ) $ 712 December 31, 2018 (in thousands, except for years) Useful Gross Accumulated Net book Developed Technology 6 $ 1,220 $ (559 ) $ 661 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (579 ) $ 661

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	6. Commitments and contingencies Litigation In February 2016, a complaint was filed in the Superior Court of the State of California (County of Santa Clara), dated February 3, 2016 on behalf of Agilent Technologies, Inc. (Agilent), against the Company and its CEO, Ms. Emily Leproust. Agilent’s complaint alleges three claims (1) alleged breach of contract, related to the use of confidential information and alleged breach of non-solicitation obligations against Ms. Leproust; (2) alleged breach of a duty of loyalty against Ms. Leproust; and (3) alleged misappropriation of trade secrets under the California Uniform Trade Secrets Act (CUTSA) against all defendants. On December 7, 2018, the Court granted Agilent’s motion to amend its complaint, permitting Agilent to file its Second Amended Complaint. The Second Amended Complaint, filed December 13, 2018, adds amended allegations against the Company and the CEO, and also new claims for breach of contract and trade secret misappropriation against two individuals: a current Company employee and a former Company employee. The Court also set trial to begin on February 24, 2020. On January 29, 2019, the Company and Ms. Leproust filed a demurrer and motion to strike Agilent’s second amended complaint, challenging each of Agilent’s claims. The hearing on the demurrer and motion to strike is currently set for May 3, 2019. Also, on January 29, 2019, the Company and Ms. Leproust filed a cross-complaint, asserting six counterclaims against Agilent and Does 1-10 for (1) declaration of no trade secret misappropriation; (2) declaration of no breach of contract; (3) declaration of no breach of duty of loyalty; (4) defamation, defamation per se, libel, libel per se, slander, and slander per se; (5) intentional interference with prospective economic advantage; (6) unlawful and unfair competition. The Company and Ms. Leproust also filed their answer and affirmative defenses to Agilent’s second amended complaint. The Company believes that Agilent’s complaint is without merit, and intends to continue vigorously defending itself. The Company is currently unable to predict the ultimate outcome of this matter or estimate a reasonably possible loss or range of loss, and no amounts have been accrued in the condensed consolidated financial statements. Indemnifications In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend the indemnified parties for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. To date, the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require it to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by corporate law. The Company also has directors’ and officers’ insurance.

Related party transactions

Related party transactions	3 Months Ended
	Dec. 31, 2018
Related Party Transactions [Abstract]
Related party transactions	7. Related party transactions During the three months ended December 31, 2017 and 2018, the Company purchased raw materials from a related party investor in the amount of $0.4 million and $1.2 million, respectively. Payable balances and cash receipts and receivable balances with the related party were immaterial as of December 31, 2018.

Income taxes

Income taxes	3 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income taxes	8. Income taxes In determining quarterly provisions for income taxes, the Company uses the annual estimated effective tax rate applied to the actual year-to-date

Warrants

Warrants	3 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Warrants	9. Warrants In connection with its long-term debt agreements, the Company issued warrants for its redeemable convertible preferred stock and common stock as follows: (in thousands, except share and per share data) Number of Fair Warrant class/series: September 30, 2018 Issuance date Expiration date Exercise price Series A 36,838 $ 365 October 8, 2013 October 8, 2023 $ 3.26 Series B 16,221 94 September 2, 2014 September 2, 2024 $ 7.84 Series C 18,854 130 December 22, 2015 December 22, 2025 $ 14.85 Series D 7,531 42 March 28, 2016 March 28, 2026 $ 21.24 Total preferred stock warrants 79,444 $ 631 Common stock warrants 64,127 $ 486 September 6, 2017 September 6, 2027 $ 6.24 (in thousands, except share and per share data) Number of Warrant class/series: December 31, Issuance date Expiration date Exercise price Common stock warrants 16,221 September 2, 2014 September 2, 2024 $ 7.84 Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Common stock warrants 32,064 September 6, 2017 September 6, 2027 $ 6.24 Total common stock warrants 74,670 In October 2018, each warrant to purchase redeemable convertible preferred stock was converted to a warrant to purchase common stock immediately prior to the completion of the IPO. In November 2018, a total of 68,901 warrants were net exercised; 36,838 warrants with an exercise price of $3.26 per common share and 32,063 warrants with an exercise price of $6.24 per common share. The transactions were a cashless exercise for a net 57,122 of common shares issued by the Company.

Redeemable convertible preferre

Redeemable convertible preferred stock	3 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Redeemable convertible preferred stock	10. Redeemable convertible preferred stock In October 2018, each share of Series A, Series B, Series C and Series D redeemable convertible preferred stock was converted into common stock immediately prior to the completion of the IPO.

Stock-based compensation

Stock-based compensation	3 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-based compensation	11. Stock-based compensation 2018 Equity Incentive Plan On September 26, 2018, the board of directors adopted the 2018 Equity Incentive Plan (the 2018 Plan) as a successor to the 2013 Stock Plan (the 2013 Plan). The maximum aggregate number of shares that may be issued under the 2018 Plan is 5,856,505 shares of the Company’s common stock. The number of shares reserved for issuance under the 2018 Plan will be increased automatically on the first day of each fiscal year, following the fiscal year in which the 2018 Plan became effective, by a number equal to the least of 999,900 shares, 4% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. The common shares issuable under the 2018 Plan were registered pursuant to a registration statement on Form S-8 on November 1, 2018. Any shares subject to outstanding awards under the 2013 Equity Incentive Plan that are cancelled or repurchased subsequent to the 2018 Plan’s effective date are returned to the pool of shares reserved for issuance under the 2018 Plan. Awards granted under the 2018 Plan may be nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, performance shares and performance units. 2018 Employee Stock Purchase Plan On September 26, 2018, the board of directors adopted the 2018 Employee Stock Purchase Plan (the 2018 ESPP). A total of 275,225 shares of the Company’s common stock have been reserved for issuance under the 2018 ESPP. The number of shares reserved for issuance under the 2018 ESPP will be increased automatically on the first day of each fiscal year, following the fiscal year in which the 2018 ESPP becomes effective, by a number equal to the least of 249,470 shares, 1% of the shares of common stock outstanding at that time, or such number of shares determined by the Company’s board of directors. Subject to any plan limitations, the 2018 ESPP allows eligible service providers (through qualified and non-qualified offerings) to contribute, normally through payroll deductions, up to 15% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The offerings periods beginning in February and August of each year, except the initial offering period which commenced with the initial public offering in October 2018 and ends on August 20, 2019. The common shares issuable under the 2018 ESPP were registered pursuant to a registration statement on Form S-8 on November 26, 2018. Unless otherwise determined by the board of directors, the Company’s common stock will be purchased for the accounts of employees participating in the 2018 ESPP at a price per share that is the lesser of 85% of the fair market value of the Company’s common stock on the first trading day of the offering period, which for the initial offering period is the price at which shares of the Company’s common stock were first sold to the public, or 85% of the fair market value of the Company’s common stock on the last trading day of the offering period. Activity under the equity incentive plans during the three months ended December 31, 2018 is summarized below: Shares Options Weighted Weighted Aggregate Outstanding at September 30, 2018 860,287 2,520,485 $ 8.22 8.38 $ 11,482,909 Additional shares authorized 2,494,700 — Stock options granted (1,038,532 ) 1,038,532 25.46 Stock options exercised — (48,841 ) 4.67 Stock options forfeited 10,136 (10,136 ) 9.52 Restricted stock units granted (395,698 ) — — Early exercised options repurchased 442 — Outstanding at December 31, 2018 1,931,335 3,500,040 13.38 8.63 $ 37,247,861 Vested or expected to vest and exercisable at December 31, 2018 3,500,040 13.38 8.63 $ 37,247,861 Total stock-based compensation expense recognized was as follows: Three months ended (in thousands) 2017 2018 Cost of revenues $ 77 $ 251 Research and development 144 300 Selling, general and administrative 315 1,313 Total stock-based compensation $ 536 $ 1,864 As of December 31, 2018, there was $31.3 million of total unrecognized compensation cost related to non-vested Restricted Stock Units Restricted stock primarily consists of restricted stock unit awards (RSUs) which have been granted to employees. The value of an RSU grant is based on the Company’s stock price on the date of grant. The shares underlying the RSU awards are not issued until the RSUs vest. Upon vesting, each RSU converts into one share of the Company’s common stock. In November 2018, the Company granted 395,698 RSUs to its employees and executive officers under the 2018 Plan of which 390,002 have a service-based vesting condition over a five-year period and 5,696 have a service-based vesting condition over a four-year period. The RSUs have a weighted average grant date fair value of $26.66. As of December 31, 2018, there was $10.4 million of total unrecognized compensation cost related to this issuance that is expected to be recognized over a weighted-average period of 4.9 years.

Net loss per share attributable

Net loss per share attributable to common stockholders	3 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Net loss per share attributable to common stockholders	12. Net loss per share attributable to common stockholders The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended December 31, (in thousands, except share and per share data) 2017 2018 Numerator: Net loss attributable to common stockholders $ (16,937 ) $ (22,639 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 2,638,068 19,187,533 Net loss per share attributable to common stockholders, basic and diluted $ (6.42 ) $ (1.18 ) The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows: Three months ended December 31, (in thousands, except share and per share data) 2017 2018 Shares subject to options to purchase common stock 1,894,028 3,500,040 Unvested restricted shares of common stock 493,756 81,473 Unvested restricted shares units of common stock — 395,698 Unvested shares of common stock issued upon early exercise of stock options 64,640 59,548 Shares subject to warrants to purchase common stock 64,127 74,670 Shares subject to warrants to purchase redeemable convertible preferred stock 79,444 — Shares of redeemable convertible preferred stock 15,091,496 — Total 17,687,491 4,111,429

Geographic, product and industr

Geographic, product and industry information	3 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Geographic, product and industry information	13. Geographic, product and industry information The table below sets forth revenues by geographic region, based on ship-to Three months ended (in thousands) 2017 2018 United States $ 3,010 $ 8,569 EMEA 1,102 2,435 APAC 151 420 North America 50 68 Total $ 4,313 $ 11,492 The table below sets forth revenues by products. Three months ended (in thousands) 2017 2018 Synthetic genes $ 3,116 $ 6,511 Oligo pools 728 810 DNA libraries 308 413 NGS tools 161 3,758 Total $ 4,313 $ 11,492 The table below sets forth revenues by industry. Three months ended (in thousands) 2017 2018 Industrial chemicals $ 2,678 $ 5,346 Academic research 964 1,972 Healthcare 568 3,981 Agricultural 103 193 Total $ 4,313 $ 11,492 Long-lived assets located in the United States were $13.1 million as of December 31, 2018. Long-lived assets located outside of the United States were $0.5 million as of December 31, 2018.

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Basis of presentation and use of estimates	Basis of presentation and use of estimates The accompanying unaudited condensed consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K The presentation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The Company’s unaudited condensed consolidated financial statements include its wholly-owned subsidiaries. All intercompany balances and accounts are eliminated in consolidation.
Significant accounting policies	Significant accounting policies There have been no material changes in the accounting policies from those disclosed in the audited consolidated financial statements and the related notes included in the Annual Report on Form 10-K.
Reverse stock split	Reverse stock split In October 2018, the Company’s stockholders approved a one-for-0.101
Deferred offering costs	Deferred offering costs Deferred offering costs, which consist of direct incremental legal, consulting, banking and accounting fees relating to the Company’s IPO, are capitalized and will be offset against proceeds from the IPO within stockholders’ equity. As of September 30, 2018, there was $3.7 million of deferred offering costs within other non-current
Recent accounting pronouncements	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued new lease accounting guidance in ASU 2016-02, Leases right-of-use In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments zero-coupon 2016-15 In November 2016, the FASB has issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash beginning-of-period end-of-period non-current (in thousands) September 30, December 31, Cash and cash equivalents $ 80,757 $ 66,459 Restricted cash, non-current 579 579 Restricted cash, current (within prepaid expenses and other current assets) 201 57 Total cash, cash equivalents and restricted cash $ 81,537 $ 67,095 Amounts included in restricted cash primarily relate to security deposits and a letter of credit with a financial institution, both in connection with office space lease agreements. In January 2017, the FASB has issued ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business In January 2017, the FASB issued ASU 2017-04, Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment. In May 2017, the FASB issued ASU 2017-09, Compensation Stock Compensation (Topic 718): Scope of Modification Accounting 2017-09, In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Subtopic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018-14

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	3 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of the Company’s cash and cash equivalents, current portion of restricted cash and non-current (in thousands) September 30, December 31, Cash and cash equivalents $ 80,757 $ 66,459 Restricted cash, non-current 579 579 Restricted cash, current (within prepaid expenses and other current assets) 201 57 Total cash, cash equivalents and restricted cash $ 81,537 $ 67,095

Fair value measurement (Tables)

Fair value measurement (Tables)	3 Months Ended
	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of September 30, 2018 and December 31, 2018 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value. September 30, 2018 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash and cash equivalents $ 46,823 $ — $ — $ 46,823 Money market funds 33,934 — — 33,934 Totals $ 80,757 $ — $ — $ 80,757 Liabilities Redeemable convertible preferred stock warrant liability $ — $ — $ 631 $ 631 December 31, 2018 (in thousands) Level 1 Level 2 Level 3 Fair value Assets Cash and cash equivalents $ 21,041 $ — $ — $ 21,041 Money market funds 39,321 — — 39,321 Corporate bonds — 2,993 — 2,993 Commercial paper — 28,707 — 28,707 U.S. government treasury bills 38,104 — — 38,104 Totals $ 98,466 $ 31,700 $ — $ 130,166
Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments	The following table provides a reconciliation of beginning and ending balances of the Level 3 instruments during the three months ended December 31, 2017 and 2018: December 31, 2017 (in thousands) Series A Series B Series C Series D Total Fair value as of September 30, 2017 $ 331 $ 110 $ 152 $ 51 $ 644 Change in fair value recorded in other income (expense), net 6 5 (12 ) (1 ) (2 ) Fair value as of December 31, 2017 $ 337 $ 115 $ 140 $ 50 $ 642 December 31, 2018 (in thousands) Series A Series B Series C Series D Total Fair value as of September 30, 2018 $ 365 $ 94 $ 130 $ 42 $ 631 Conversion of redeemable convertible preferred stock warrants to common stock warrants (365 ) (94 ) (130 ) (42 ) (631 ) Fair value as of December 31, 2018 $ — $ — $ — $ — $ —

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Dec. 31, 2018
Inventory Disclosure [Abstract]
Summary of Inventory	Inventory consists of the following: (in thousands) September 30, December 31, Raw Materials $ 2,988 $ 3,351 Work-in-process 2,273 1,599 Finished Goods 767 611 $ 6,028 $ 5,561

Goodwill and intangible assets

Goodwill and intangible assets (Tables)	3 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets Balances	The intangible assets balances are presented below: September 30, 2018 (in thousands, except for years) Useful Gross Accumulated Net book Developed Technology 6 $ 1,220 $ (508 ) $ 712 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (528 ) $ 712 December 31, 2018 (in thousands, except for years) Useful Gross Accumulated Net book Developed Technology 6 $ 1,220 $ (559 ) $ 661 Tradenames & Trademarks 2 20 (20 ) — Total indefinite-lived intangible assets $ 1,240 $ (579 ) $ 661

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Dec. 31, 2018
Text Block [Abstract]
Summary of Issued Warrants for Its Redeemable Convertible Preferred Stock and Common Stock	In connection with its long-term debt agreements, the Company issued warrants for its redeemable convertible preferred stock and common stock as follows: (in thousands, except share and per share data) Number of Fair Warrant class/series: September 30, 2018 Issuance date Expiration date Exercise price Series A 36,838 $ 365 October 8, 2013 October 8, 2023 $ 3.26 Series B 16,221 94 September 2, 2014 September 2, 2024 $ 7.84 Series C 18,854 130 December 22, 2015 December 22, 2025 $ 14.85 Series D 7,531 42 March 28, 2016 March 28, 2026 $ 21.24 Total preferred stock warrants 79,444 $ 631 Common stock warrants 64,127 $ 486 September 6, 2017 September 6, 2027 $ 6.24 (in thousands, except share and per share data) Number of Warrant class/series: December 31, Issuance date Expiration date Exercise price Common stock warrants 16,221 September 2, 2014 September 2, 2024 $ 7.84 Common stock warrants 18,854 December 22, 2015 December 22, 2025 $ 14.85 Common stock warrants 7,531 March 28, 2016 March 28, 2026 $ 21.24 Common stock warrants 32,064 September 6, 2017 September 6, 2027 $ 6.24 Total common stock warrants 74,670

Stock-based compensation (Table

Stock-based compensation (Tables)	3 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Activity Under The Equity Incentive Plans	Activity under the equity incentive plans during the three months ended December 31, 2018 is summarized below: Shares Options Weighted Weighted Aggregate Outstanding at September 30, 2018 860,287 2,520,485 $ 8.22 8.38 $ 11,482,909 Additional shares authorized 2,494,700 — Stock options granted (1,038,532 ) 1,038,532 25.46 Stock options exercised — (48,841 ) 4.67 Stock options forfeited 10,136 (10,136 ) 9.52 Restricted stock units granted (395,698 ) — — Early exercised options repurchased 442 — Outstanding at December 31, 2018 1,931,335 3,500,040 13.38 8.63 $ 37,247,861 Vested or expected to vest and exercisable at December 31, 2018 3,500,040 13.38 8.63 $ 37,247,861
Total Stock-based Compensation Expense	Total stock-based compensation expense recognized was as follows: Three months ended (in thousands) 2017 2018 Cost of revenues $ 77 $ 251 Research and development 144 300 Selling, general and administrative 315 1,313 Total stock-based compensation $ 536 $ 1,864

Net loss per share attributab_2

Net loss per share attributable to common stockholders (Tables)	3 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders: Three months ended December 31, (in thousands, except share and per share data) 2017 2018 Numerator: Net loss attributable to common stockholders $ (16,937 ) $ (22,639 ) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 2,638,068 19,187,533 Net loss per share attributable to common stockholders, basic and diluted $ (6.42 ) $ (1.18 )
Summary of Calculation of Diluted Net Loss Per Share	The potentially dilutive common shares that were excluded from the calculation of diluted net loss per share because their effect would have been antidilutive for the periods presented are as follows: Three months ended December 31, (in thousands, except share and per share data) 2017 2018 Shares subject to options to purchase common stock 1,894,028 3,500,040 Unvested restricted shares of common stock 493,756 81,473 Unvested restricted shares units of common stock — 395,698 Unvested shares of common stock issued upon early exercise of stock options 64,640 59,548 Shares subject to warrants to purchase common stock 64,127 74,670 Shares subject to warrants to purchase redeemable convertible preferred stock 79,444 — Shares of redeemable convertible preferred stock 15,091,496 — Total 17,687,491 4,111,429

Geographic, product and indus_2

Geographic, product and industry information (Tables)	3 Months Ended
	Dec. 31, 2018
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	The table below sets forth revenues by geographic region, based on ship-to Three months ended (in thousands) 2017 2018 United States $ 3,010 $ 8,569 EMEA 1,102 2,435 APAC 151 420 North America 50 68 Total $ 4,313 $ 11,492
Summary of Revenue by Product	The table below sets forth revenues by products. Three months ended (in thousands) 2017 2018 Synthetic genes $ 3,116 $ 6,511 Oligo pools 728 810 DNA libraries 308 413 NGS tools 161 3,758 Total $ 4,313 $ 11,492
Summary of Revenue by Industry	The table below sets forth revenues by industry. Three months ended (in thousands) 2017 2018 Industrial chemicals $ 2,678 $ 5,346 Academic research 964 1,972 Healthcare 568 3,981 Agricultural 103 193 Total $ 4,313 $ 11,492

The Company - Additional Inform

The Company - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended
	Oct. 31, 2018	Dec. 31, 2018	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit		$ (233,494)	$ (210,855)
Initial public offering (IPO) of common stock	$ 69,600

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2018	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)
Accounting Policies [Abstract]
Reverse stock split description	One-for-0.101
Reverse stock split ratio	0.101
Deferred offering costs included in non-current assets			$ 3.7
Additional deferred offering costs incurred		$ 1.6

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017	[1]	Sep. 30, 2017	[1]
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and cash equivalents	$ 66,459	$ 80,757
Restricted cash, non-current	579	579
Restricted cash, current (within prepaid expenses and other current assets)	57	201
Total cash, cash equivalents and restricted cash	$ 67,095	$ 81,537	$ 26,290		$ 31,429
[1]	Adjusted to reflect the retrospective adoption of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Assets
Assets, Totals	$ 130,166	$ 80,757
Corporate Bonds [Member]
Assets
Assets, Totals	2,993
Commercial Paper [Member]
Assets
Assets, Totals	28,707
US Government Treasury Bills [Member]
Assets
Assets, Totals	38,104
Redeemable Convertible Preferred Stock Warrant Liability [Member]
Liabilities
Redeemable convertible preferred stock warrant liability		631
Cash and Cash Equivalents [Member]
Assets
Assets, Totals	21,041	46,823
Money Market Funds [Member]
Assets
Assets, Totals	39,321	33,934
Fair Value, Inputs, Level 1 [Member]
Assets
Assets, Totals	98,466	80,757
Fair Value, Inputs, Level 1 [Member] | US Government Treasury Bills [Member]
Assets
Assets, Totals	38,104
Fair Value, Inputs, Level 1 [Member] | Cash and Cash Equivalents [Member]
Assets
Assets, Totals	21,041	46,823
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Assets
Assets, Totals	39,321	33,934
Fair Value, Inputs, Level 2 [Member]
Assets
Assets, Totals	31,700
Fair Value, Inputs, Level 2 [Member] | Corporate Bonds [Member]
Assets
Assets, Totals	2,993
Fair Value, Inputs, Level 2 [Member] | Commercial Paper [Member]
Assets
Assets, Totals	$ 28,707
Fair Value, Inputs, Level 3 [Member] | Redeemable Convertible Preferred Stock Warrant Liability [Member]
Liabilities
Redeemable convertible preferred stock warrant liability		$ 631

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Reconciliation of Beginning and Ending Balances of the Level 3 Instruments (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning balance	$ 631	$ 644
Conversion of redeemable convertible preferred stock warrants to common stock warrants	(631)
Change in fair value recorded in other income (expense), net		(2)
Fair value, ending balance		642
Series A Redeemable Convertible Preferred Stock [Member]
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning balance	365	331
Conversion of redeemable convertible preferred stock warrants to common stock warrants	(365)
Change in fair value recorded in other income (expense), net		6
Fair value, ending balance		337
Series B Redeemable Convertible Preferred Stock [Member]
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning balance	94	110
Conversion of redeemable convertible preferred stock warrants to common stock warrants	(94)
Change in fair value recorded in other income (expense), net		5
Fair value, ending balance		115
Series C Redeemable Convertible Preferred Stock [Member]
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning balance	130	152
Conversion of redeemable convertible preferred stock warrants to common stock warrants	(130)
Change in fair value recorded in other income (expense), net		(12)
Fair value, ending balance		140
Series D Redeemable Convertible Preferred Stock [Member]
Fair Value, Instruments Classified in Shareholders' Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value, beginning balance	42	51
Conversion of redeemable convertible preferred stock warrants to common stock warrants	$ (42)
Change in fair value recorded in other income (expense), net		(1)
Fair value, ending balance		$ 50

Inventory - Summary of Inventor

Inventory - Summary of Inventory (Detail) - USD ($) $ in Thousands	Dec. 31, 2018	Sep. 30, 2018
Inventory, Net [Abstract]
Raw Materials	$ 3,351	$ 2,988
Work-in-process	1,599	2,273
Finished Goods	611	767
Total inventories	$ 5,561	$ 6,028

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill And Intangible Assets [Line Items]
Changes in carrying value of goodwill	$ 0	$ 0
Maximum [Member]
Goodwill And Intangible Assets [Line Items]
Total amortization expense related to intangible assets	$ 100,000	$ 100,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Summary of Intangible Assets Balances (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Acquired Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,240	$ 1,240
Accumulated amortization	(579)	(528)
Net book value	$ 661	$ 712
Developed Technology [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	6 years	6 years
Gross carrying amount	$ 1,220	$ 1,220
Accumulated amortization	(559)	(508)
Net book value	$ 661	$ 712
Tradenames & Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Useful life in years	2 years	2 years
Gross carrying amount	$ 20	$ 20
Accumulated amortization	$ (20)	$ (20)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Related Party Transactions [Abstract]
Raw materials purchased from related party investor	$ 1.2	$ 0.4
Description of related party transactions	During the three months ended December 31, 2017 and 2018, the Company purchased raw materials from a related party investor in the amount of $0.4 million and $1.2 million, respectively. Payable balances and cash receipts and receivable balances with the related party were immaterial as of December 31, 2018.

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Provisions for income taxes	$ 43,000	$ 52,000
Maximum [Member]
Income Tax Disclosure [Line Items]
Provisions for income taxes	$ 100,000	$ 100,000

Warrants - Summary of Issued Wa

Warrants - Summary of Issued Warrants for Its Redeemable Convertible Preferred Stock and Common Stock (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2018	Nov. 30, 2018
Class of Warrant or Right [Line Items]
Fair Value	[1]		$ (2)
Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants					36,838
Exercise price per share					$ 3.26
Warrants Two [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants					32,063
Exercise price per share					$ 6.24
Series A Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants				36,838
Fair Value				$ 365
Issuance date				Oct. 8, 2013
Expiration date				Oct. 8, 2023
Exercise price per share				$ 3.26
Series B Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants				16,221
Fair Value				$ 94
Issuance date				Sep. 2, 2014
Expiration date				Sep. 2, 2024
Exercise price per share				$ 7.84
Series C Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants				18,854
Fair Value				$ 130
Issuance date				Dec. 22, 2015
Expiration date				Dec. 22, 2025
Exercise price per share				$ 14.85
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants				7,531
Fair Value				$ 42
Issuance date				Mar. 28, 2016
Expiration date				Mar. 28, 2026
Exercise price per share				$ 21.24
Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants				79,444
Fair Value				$ 631
Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants		74,670		64,127
Fair Value				$ 486
Issuance date				Sep. 6, 2017
Expiration date				Sep. 6, 2027
Exercise price per share				$ 6.24
Common Stock [Member] | Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants		16,221
Issuance date		Sep. 2, 2014
Expiration date		Sep. 2, 2024
Exercise price per share		$ 7.84
Common Stock [Member] | Warrants Two [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants		18,854
Issuance date		Dec. 22, 2015
Expiration date		Dec. 22, 2025
Exercise price per share		$ 14.85
Common Stock [Member] | Warrants Three [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants		7,531
Issuance date		Mar. 28, 2016
Expiration date		Mar. 28, 2026
Exercise price per share		$ 21.24
Common Stock [Member] | Warrants Four [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants		32,064
Issuance date		Sep. 6, 2017
Expiration date		Sep. 6, 2027
Exercise price per share		$ 6.24
[1]	Adjusted to reflect the retrospective adoption of Accounting Standards Update (ASU) 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash.

Warrants - Additional Informati

Warrants - Additional Information (Detail)	1 Months Ended
	Nov. 30, 2018$ / sharesshares
Class of Warrant or Right [Line Items]
Net exercise of stock warrants	68,901
Common stock issued for cashless exercise	57,122
Warrants One [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	36,838
Exercise price per share | $ / shares	$ 3.26
Warrants Two [Member]
Class of Warrant or Right [Line Items]
Number of shares underlying warrants	32,063
Exercise price per share | $ / shares	$ 6.24

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 26, 2018	Nov. 30, 2018	Dec. 31, 2018	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of common stock shares issued			100,000,000	27,775,000
Unrecognized compensation cost, stock options			$ 31.3
Unrecognized stock-based compensation expense, period for recognition			3 years 9 months
2018 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	999,900
Annual automatic Increase in share reserved for issuance	4.00%
2018 Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate number of common stock shares issued	5,856,505
2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum annual increase in share reserved for issuance	249,470
Annual automatic Increase in share reserved for issuance	1.00%
Aggregate number of common stock shares issued	275,225
2018 ESPP [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of payroll deduction to purchase common stock	15.00%
2015 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP eligible employee common stock purchase price ratio	85.00%
Restricted Stock Units (RSUs) [Member] | 2018 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, stock options			$ 10.4
Unrecognized stock-based compensation expense, period for recognition			4 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award Grants in Period		395,698
Share-based Compensation Arrangement by Share-based Payment Award Weighted Average Grant Date Fair Value		$ 26.66
Restricted Stock Units (RSUs) [Member] | 2018 ESPP [Member] | Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Vested, share		390,002
Share-based Compensation Arrangement by Share-based Payment Award Vested period		5 years
Restricted Stock Units (RSUs) [Member] | 2018 ESPP [Member] | Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award Vested, share		5,696
Share-based Compensation Arrangement by Share-based Payment Award Vested period		4 years

Stock-based compensation - Acti

Stock-based compensation - Activity Under The Equity Incentive Plans (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares available, Outstanding Beginning Balance	860,287
Shares available, Additional shares authorized	2,494,700
Shares available, Stock options granted	(1,038,532)
Shares available, Stock options forfeited	10,136
Shares available, Restricted stock units granted	(395,698)
Shares available, Early exercised options repurchased	442
Shares available, Outstanding Ending Balance	1,931,335	860,287
Number of options, Outstanding beginning balance	2,520,485
Options outstanding, Stock options granted	1,038,532
Options outstanding, Stock options exercised	(48,841)
Options outstanding, Stock options forfeited	(10,136)
Number of options, Outstanding ending balance	3,500,040	2,520,485
Vested or expected to vest and exercisable	3,500,040
Weighted average exercise price per share, Outstanding Beginning Balance	$ 8.22
Weighted average exercise price per share, Stock options granted	25.46
Weighted average exercise price per share, Stock options exercised	4.67
Weighted average exercise price per share, Stock options forfeited	9.52
Weighted average exercise price per share, Outstanding Ending Balance	13.38	$ 8.22
Weighted average exercise price per share, Vested or expected to vest and exercisable	$ 13.38
Weighted average remaining contractual term, Outstanding	8 years 7 months 17 days	8 years 4 months 17 days
Weighted average remaining contractual term, Vested or expected to vest and exercisable	8 years 7 months 17 days
Aggregate intrinsic value, Outstanding	$ 37,247,861	$ 11,482,909
Aggregate intrinsic value, Outstanding Vested or expected to vest and exercisable	$ 37,247,861

Stock-based compensation - Tota

Stock-based compensation - Total Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 1,864	$ 536
Cost of Revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	251	77
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	300	144
Selling, General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation expense	$ 1,313	$ 315

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of the Company's Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Numerator:
Net loss attributable to common stockholders	$ (22,639)	$ (16,937)
Denominator:
Weighted average shares used in computing net loss per share, basic and diluted	19,187,533	2,638,068
Net loss per share attributable to common stockholders, basic and diluted	$ (1.18)	$ (6.42)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Summary of Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	4,111,429	17,687,491
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		15,091,496
Options To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	3,500,040	1,894,028
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	81,473	493,756
Restricted Share Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	395,698
Early Exercise Of Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	59,548	64,640
Warrants To Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	74,670	64,127
Warrants to Purchase Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share amount		79,444

Geographic, Product and Indus_3

Geographic, Product and Industry Information - Summary of Revenue by Geographic Region (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 11,492	$ 4,313
United States [Member]
Segment Reporting Information [Line Items]
Revenue	8,569	3,010
EMEA [Member]
Segment Reporting Information [Line Items]
Revenue	2,435	1,102
Asia Pacific [Member]
Segment Reporting Information [Line Items]
Revenue	420	151
North America [Member]
Segment Reporting Information [Line Items]
Revenue	$ 68	$ 50

Geographic, Product and Indus_4

Geographic, Product and Industry Information - Summary of Revenue by Product (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 11,492	$ 4,313
Synthetic Genes [Member]
Segment Reporting Information [Line Items]
Revenue	6,511	3,116
Oligo Pools [Member]
Segment Reporting Information [Line Items]
Revenue	810	728
DNA Libraries [Member]
Segment Reporting Information [Line Items]
Revenue	413	308
NGS Tools [Member]
Segment Reporting Information [Line Items]
Revenue	$ 3,758	$ 161

Geographic, Product and Indus_5

Geographic, Product and Industry Information - Summary of Revenue by Industry (Detail) - USD ($) $ in Thousands	3 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Segment Reporting Information [Line Items]
Revenue	$ 11,492	$ 4,313
Industrial Chemicals [Member]
Segment Reporting Information [Line Items]
Revenue	5,346	2,678
Academic Research [Member]
Segment Reporting Information [Line Items]
Revenue	1,972	964
Health Care [Member]
Segment Reporting Information [Line Items]
Revenue	3,981	568
Agricultural [Member]
Segment Reporting Information [Line Items]
Revenue	$ 193	$ 103

Geographic, Product and Indus_6

Geographic, Product and Industry Information - Additional Information (Detail) $ in Millions	Dec. 31, 2018USD ($)
United States [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 13.1
Non-US [Member]
Segment Reporting Information [Line Items]
Long-lived assets	$ 0.5